ArticleClinical immunology (Orlando, Fla.)2008
Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.
Article in Clinical immunology (Orlando, Fla.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- The in-vitro effect of bovine milk, and plant-based alternatives on oral microorganisms and biofilms.Scientific reports · 2026Article
- Curcumin modulates purinergic signaling and inflammatory response in cutaneous metastatic melanoma cells.Purinergic signalling · 2025Article
- Recent Advances in Immune Regulation by Targeting Dendritic Cells using Small Interfering RNAs.Current molecular medicine · 2025Review
- Article
- In Vitro Study on Green Propolis as a Potential Ingredient of Oral Health Care Products.Antibiotics (Basel, Switzerland) · 2022Article
- Review
- Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10.Frontiers in immunology · 2018Review
- Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Frontiers in immunology · 2017Review
- Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy.Frontiers in immunology · 2017Review
- Immune evasion pathways and the design of dendritic cell-based cancer vaccines.Discovery medicine · 2016Review
- Article
- Engineering better immunotherapies via RNA interference.Human vaccines & immunotherapeutics · 2014Review
- Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.Immunologic research · 2011Article
- Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.Cancers · 2011Article
- RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy.Molecular biology reports · 2010Review
- Dendritic Cells Loaded with Tumor Antigens and a Dual Immunostimulatory and Anti-Interleukin 10-Specific Small Interference RNA Prime T Lymphocytes against Leukemic Cells.Translational oncology · 2009Article
- Interleukin-10: new perspectives on an old cytokine.Immunological reviews · 2008Review
- CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Dendritic cells (DC) present antigenic epitopes to and activate T cells. They also polarize the ensuing T cell response to Th1 or Th2 type response, depending on their cytokine production profile. For example, IL-12 producing DC generate Th1 type T cell response whereas IL-10 producing DC is usually tolerogenic. Different strategies--such as the use of cytokines and anti-cytokine antibodies, dominant negative forms of protein, anti-sense RNA etc.--have been employed to influence the cytokine synthetic profile of DC as well as to make DC more immunogenic. Utilizing GFP expressing recombinant adenoviruses in association with lipid-mediated transfection of siRNA, we have silenced the endogenous IL-10 gene in DC. We show that IL-10 gene silenced DC produces more IL-12 and also generates a better cytolytic T cell response against the human melanoma associated epitope, MART-1(27-35), in vitro. We also show that the GFP expressing adenoviral vector can be used to optimize the parameters for siRNA delivery in primary cells and show that RNA interference methodology can efficiently knock down virus encoded genes transcribed at very high multiplicity of infection in DC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.